Annovis Bio (NYSEAMERICAN:ANVS) specializes in developing novel therapies aimed at treating neurodegenerative disorders such as Alzheimer’s and Parkinson’s disease. This pioneering venture focuses on addressing the underlying causes of these debilitating conditions, striving to halt or reverse the progression of symptoms. Annovis Bio’s projects are centered on its innovative lead compound, aiming to improve cognitive and motor functions in affected individuals. Through rigorous research and development, the company’s objective is to offer groundbreaking treatments that can significantly enhance the quality of life for patients grappling with these challenging disorders, marking a substantial step forward in neurodegenerative disease management.